$55.45
0.78%
Nasdaq, Nov 18, 04:00 pm EST. Closed.
ISIN
US04963C2098
Symbol
ATRC

AtriCure, Inc. Stock price

$55.45
-0.08 0.14% 1M
+26.97 94.70% 6M
+15.89 40.17% YTD
+22.29 67.22% 1Y
+13.51 32.21% 3Y
-21.32 27.77% 5Y
+35.46 177.39% 10Y
+47.10 564.07% 20Y
Nasdaq, Closing price Wed, Nov 18 2026
+0.43 0.78%

Is AtriCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.7b
Net debt
positive
Cash
$187.0m
Shares outstanding
50.9m
Valuation
P/E
184.8
P/S | estimate
4.8 | 4.6
EV/Sales | estimate
4.6 | 4.4
EV/FCF | ex SBC
57.5 | 24,793.0
P/B
5.3
Financial Health
Equity Ratio
75.2%
Return on Equity
-2.3%
ROCE
2.7%
ROIC
3.1%
Debt/Equity
0.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$47.3m | 8.0%
SBC as % of FCF
99.7%
SBC Growth 1Y
8.0%
Share Count Growth 1Y
2.4%
Shareholder Yield
-2.4%
Financials
Revenue | estimate
$589.8m | $620.5m
EBITDA
$20.0m
EBIT
$17.0m
Net Income
$14.9m
Free Cash Flow | ex SBC
$47.4m | $110.0k
Growth
Revenue | estimate
13.8% | 16.1%
EBITDA
183.7%
EBIT
163.2%
Net Income
151.0%
Free Cash Flow
191.8%
Margin
Gross
76.7%
EBITDA
3.4%
EBIT
2.9%
Net
2.5%
Free Cash Flow | ex SBC
8.0% | 0.0%
More
EPS
$0.3
FCF per Share
$0.9
Short interest
10.0%
Employees
1k
Rev per Employee
$400.0k

AtriCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a AtriCure, Inc. forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a AtriCure, Inc. forecast:

Buy
73%
Hold
27%

AtriCure, Inc. Events

Past Events
NOV
9
2026 UBS Global Healthcare Conference
10 days ago
NOV
3
Q3 2026 Earnings Call
16 days ago
JUL
23
Q2 2026 Earnings Call
4 months ago
JUN
10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
FEB
17
Q4 2025 Earnings Call
9 months ago
JAN
14
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
OCT
29
Q3 2025 Earnings Call
about one year ago

Financial data from AtriCure, Inc.

Sep '26
+/-
%
590 590
14% 14%
100%
- Direct Costs 137 137
5% 5%
23%
453 453
17% 17%
77%
- Selling and Administrative Expenses 328 328
8% 8%
56%
- Research and Development Expense 104 104
3% 3%
18%
20 20
184% 184%
3%
- Depreciation and Amortization 2.96 2.96
3% 3%
1%
EBIT (Operating Income) EBIT 17 17
163% 163%
3%
Net Profit 15 15
151% 151%
3%

In millions USD.

Don't miss a Thing! We will send you all news about AtriCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AtriCure, Inc. Stock News

Neutral
Business Wire
●
2 days ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 38th Annual Healthcare Conference. AtriCure's management is scheduled to participate i...
Neutral
Business Wire
●
16 days ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results. “Our third quarter results demonstrate the strength of our broad portfolio and our team's disciplined execution,” said...
More AtriCure, Inc. News

Company Profile

AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Head office United States
CEO Mr. Carrel
Employees 1,350
Founded 1994
Website www.atricure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today